1. Home
  2. WALD vs CABA Comparison

WALD vs CABA Comparison

Compare WALD & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waldencast plc

WALD

Waldencast plc

N/A

Current Price

$1.51

Market Cap

246.7M

ML Signal

N/A

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

N/A

Current Price

$3.31

Market Cap

319.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WALD
CABA
Founded
1988
2017
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
246.7M
319.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
WALD
CABA
Price
$1.51
$3.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$4.30
$14.57
AVG Volume (30 Days)
49.7K
2.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.03
N/A
Revenue Next Year
$10.43
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.45
$0.99
52 Week High
$3.45
$3.78

Technical Indicators

Market Signals
Indicator
WALD
CABA
Relative Strength Index (RSI) 36.07 58.76
Support Level $1.48 $2.11
Resistance Level $2.06 $3.34
Average True Range (ATR) 0.10 0.27
MACD -0.02 -0.02
Stochastic Oscillator 12.82 53.03

Price Performance

Historical Comparison
WALD
CABA

About WALD Waldencast plc

Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: